Current strategies for the treatment of intracranial atherosclerotic internal carotid artery stenosis

Toral R. Patel, Ketan R. Bulsara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We evaluate the current literature regarding treatment of intracranial atherosclerotic disease, with particular emphasis on emerging medical, surgical, and endovascular trials. A MEDLINE and PubMed search of the literature related to intracranial atherosclerotic disease was performed. Articles which discussed medical, surgical, and endovascular therapies were reviewed. Currently, best medical management of intracranial atherosclerotic stenosis consists of aspirin therapy. Despite this, a significant percentage of patients with high-grade stenoses experience recurrent stroke soon after their initial event. Although previous randomized trials demonstrated no benefit to performing intracranial-extracranial bypass surgery in patients with intracranial atherosclerotic stenosis, current studies seem to suggest a benefit in a particular subset of these patients, specifically those with hemodynamic compromise. Endovascular therapy for intracranial atherosclerotic stenosis is in its infancy but is beginning to show technical promise. Nonetheless, real concerns exist regarding rates of in-stent restenosis, and large-scale follow-up studies must be completed before the true efficacy of endovascular therapies can be evaluated. Symptomatic intracranial atherosclerotic stenosis is associated with considerable morbidity and mortality. However, in a subgroup of patients, specifically those with high-grade stenoses and hemodynamic compromise, the risk of morbidity and mortality is significantly higher. It is this group of patients that would most benefit from more aggressive interventions, as best medical therapy still results in a significant rate of recurrent strokes. The emergence of improved surgical and endovascular techniques will be of particular importance in treating these high-risk patients.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalNeurosurgical Review
Volume32
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Carotid Stenosis
Pathologic Constriction
Therapeutics
Hemodynamics
Stroke
Morbidity
Endovascular Procedures
Mortality
PubMed
MEDLINE
Aspirin
Stents

Keywords

  • Cerebral bypass
  • Intracranial atherosclerotic stenosis
  • Intracranial stenting
  • Revascularization
  • STA-MCA bypass
  • Stroke
  • Wingspan

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Current strategies for the treatment of intracranial atherosclerotic internal carotid artery stenosis. / Patel, Toral R.; Bulsara, Ketan R.

In: Neurosurgical Review, Vol. 32, No. 1, 01.2009, p. 23-27.

Research output: Contribution to journalArticle

@article{5529da4e1d5944d1bc7b6a3715c90a96,
title = "Current strategies for the treatment of intracranial atherosclerotic internal carotid artery stenosis",
abstract = "We evaluate the current literature regarding treatment of intracranial atherosclerotic disease, with particular emphasis on emerging medical, surgical, and endovascular trials. A MEDLINE and PubMed search of the literature related to intracranial atherosclerotic disease was performed. Articles which discussed medical, surgical, and endovascular therapies were reviewed. Currently, best medical management of intracranial atherosclerotic stenosis consists of aspirin therapy. Despite this, a significant percentage of patients with high-grade stenoses experience recurrent stroke soon after their initial event. Although previous randomized trials demonstrated no benefit to performing intracranial-extracranial bypass surgery in patients with intracranial atherosclerotic stenosis, current studies seem to suggest a benefit in a particular subset of these patients, specifically those with hemodynamic compromise. Endovascular therapy for intracranial atherosclerotic stenosis is in its infancy but is beginning to show technical promise. Nonetheless, real concerns exist regarding rates of in-stent restenosis, and large-scale follow-up studies must be completed before the true efficacy of endovascular therapies can be evaluated. Symptomatic intracranial atherosclerotic stenosis is associated with considerable morbidity and mortality. However, in a subgroup of patients, specifically those with high-grade stenoses and hemodynamic compromise, the risk of morbidity and mortality is significantly higher. It is this group of patients that would most benefit from more aggressive interventions, as best medical therapy still results in a significant rate of recurrent strokes. The emergence of improved surgical and endovascular techniques will be of particular importance in treating these high-risk patients.",
keywords = "Cerebral bypass, Intracranial atherosclerotic stenosis, Intracranial stenting, Revascularization, STA-MCA bypass, Stroke, Wingspan",
author = "Patel, {Toral R.} and Bulsara, {Ketan R.}",
year = "2009",
month = "1",
doi = "10.1007/s10143-008-0172-2",
language = "English (US)",
volume = "32",
pages = "23--27",
journal = "Neurosurgical Review",
issn = "0344-5607",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Current strategies for the treatment of intracranial atherosclerotic internal carotid artery stenosis

AU - Patel, Toral R.

AU - Bulsara, Ketan R.

PY - 2009/1

Y1 - 2009/1

N2 - We evaluate the current literature regarding treatment of intracranial atherosclerotic disease, with particular emphasis on emerging medical, surgical, and endovascular trials. A MEDLINE and PubMed search of the literature related to intracranial atherosclerotic disease was performed. Articles which discussed medical, surgical, and endovascular therapies were reviewed. Currently, best medical management of intracranial atherosclerotic stenosis consists of aspirin therapy. Despite this, a significant percentage of patients with high-grade stenoses experience recurrent stroke soon after their initial event. Although previous randomized trials demonstrated no benefit to performing intracranial-extracranial bypass surgery in patients with intracranial atherosclerotic stenosis, current studies seem to suggest a benefit in a particular subset of these patients, specifically those with hemodynamic compromise. Endovascular therapy for intracranial atherosclerotic stenosis is in its infancy but is beginning to show technical promise. Nonetheless, real concerns exist regarding rates of in-stent restenosis, and large-scale follow-up studies must be completed before the true efficacy of endovascular therapies can be evaluated. Symptomatic intracranial atherosclerotic stenosis is associated with considerable morbidity and mortality. However, in a subgroup of patients, specifically those with high-grade stenoses and hemodynamic compromise, the risk of morbidity and mortality is significantly higher. It is this group of patients that would most benefit from more aggressive interventions, as best medical therapy still results in a significant rate of recurrent strokes. The emergence of improved surgical and endovascular techniques will be of particular importance in treating these high-risk patients.

AB - We evaluate the current literature regarding treatment of intracranial atherosclerotic disease, with particular emphasis on emerging medical, surgical, and endovascular trials. A MEDLINE and PubMed search of the literature related to intracranial atherosclerotic disease was performed. Articles which discussed medical, surgical, and endovascular therapies were reviewed. Currently, best medical management of intracranial atherosclerotic stenosis consists of aspirin therapy. Despite this, a significant percentage of patients with high-grade stenoses experience recurrent stroke soon after their initial event. Although previous randomized trials demonstrated no benefit to performing intracranial-extracranial bypass surgery in patients with intracranial atherosclerotic stenosis, current studies seem to suggest a benefit in a particular subset of these patients, specifically those with hemodynamic compromise. Endovascular therapy for intracranial atherosclerotic stenosis is in its infancy but is beginning to show technical promise. Nonetheless, real concerns exist regarding rates of in-stent restenosis, and large-scale follow-up studies must be completed before the true efficacy of endovascular therapies can be evaluated. Symptomatic intracranial atherosclerotic stenosis is associated with considerable morbidity and mortality. However, in a subgroup of patients, specifically those with high-grade stenoses and hemodynamic compromise, the risk of morbidity and mortality is significantly higher. It is this group of patients that would most benefit from more aggressive interventions, as best medical therapy still results in a significant rate of recurrent strokes. The emergence of improved surgical and endovascular techniques will be of particular importance in treating these high-risk patients.

KW - Cerebral bypass

KW - Intracranial atherosclerotic stenosis

KW - Intracranial stenting

KW - Revascularization

KW - STA-MCA bypass

KW - Stroke

KW - Wingspan

UR - http://www.scopus.com/inward/record.url?scp=56049116436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049116436&partnerID=8YFLogxK

U2 - 10.1007/s10143-008-0172-2

DO - 10.1007/s10143-008-0172-2

M3 - Article

C2 - 18818960

AN - SCOPUS:56049116436

VL - 32

SP - 23

EP - 27

JO - Neurosurgical Review

JF - Neurosurgical Review

SN - 0344-5607

IS - 1

ER -